{"id":101807,"date":"2026-11-16T00:55:30","date_gmt":"2026-11-16T00:55:30","guid":{"rendered":"https:\/\/newsvog.com\/ur\/101807"},"modified":"2026-11-16T00:55:32","modified_gmt":"2026-11-16T00:55:32","slug":"us-fda-declines-to-approve-summit-lung-cancer-drug-after-trial-misses-key-survival-goal","status":"publish","type":"post","link":"https:\/\/newsvog.com\/ur\/101807","title":{"rendered":"US FDA declines to approve Summit lung cancer drug after trial misses key survival goal"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div style=\"font-size:16px;line-height:1.6\">\n<p><strong>The US Food and Drug Administration (FDA) on Sunday declined to \u200capprove Summit Therapeutics\u2019 lung cancer drug ivonescimab, a setback for efforts to expand treatment for patients whose cancer has progressed after earlier therapies.<\/strong><\/p>\n<p><span>In its so-called complete response letter, the FDA cited a late-stage trial showing that, while ivonescimab significantly delayed \u200bdisease progression, it did not demonstrate a statistically significant improvement in overall survival.<\/span><\/p>\n<p><span>Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.<\/span><\/p>\n<p><span>The decision follows the \u200bdrug\u2019s failure to achieve statistical significance on overall survival, a key measure of long-term \u2060treatment benefit, in a late-stage study that formed part of Summit\u2019s marketing application.<\/span><\/p>\n<p><span>The agency concluded that \u200bthe progression-free survival benefit alone did not support a favorable benefit-risk profile for approval.<\/span><\/p>\n<p><span>The FDA\u2019s decision was based \u200bon a late-stage study in which ivonescimab, combined with chemotherapy, reduced the risk of disease progression or death by 48%, compared with chemotherapy alone. However, the primary analysis did not show a statistically significant improvement in overall survival, or OS, which measures \u200bhow long patients live after starting treatment. Summit later submitted updated survival data to the FDA that \u200bit said showed consistent improvement across Asian and Western patients.<\/span><\/p>\n<p><span>Summit has argued that longer follow-up supports the drug\u2019s benefit, citing \u200cupdated \u2060analyses that pointed to a lower risk of death across Western and Asian patient subgroups.<\/span><\/p>\n<p><span>The \u201csubsequently matured OS dataset, consistency between Western and Asian patients, lack of new safety signals, and management\u2019s previously characterized constructive regulatory interactions strengthen the package versus the original analysis,\u201d TD Cowen analysts said earlier this month.<\/span><\/p>\n<p><span>Ivonescimab is designed to \u200bblock two proteins: PD-1, which \u200bhelps cancer evade \u2060the immune system, and VEGF, which tumors use to grow blood vessels, helping the immune system better find and attack cancer cells.<\/span><\/p>\n<p><span>Summit acquired rights to ivonescimab in \u200bthe United States, Canada, Europe and Japan from China\u2019s Akeso in 2022 under \u200ba deal \u2060valued at up to $5 billion. Akeso retained rights in China and other markets.<\/span><\/p>\n<p><span>AstraZeneca said in September it would invest $2 billion in Summit and collaborate on studies combining ivonescimab with its antibody-drug conjugate cancer therapies.<\/span><\/p>\n<p><span>Other approved treatments for \u2060the condition \u200binclude Johnson &amp; Johnson\u2019s (JNJ.N), opens new tab chemotherapy-free treatment combination with Rybrevant and AstraZeneca\u2019s \u200bTagrisso. Summit is expected to report late-stage data from a separate study in patients with a different type of lung cancer by \u200byear-end.<\/span><\/p>\n<p>\u00a0<\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/arynews.tv\/us-fda-declines-to-approve-summit-lung-cancer-drug-after-trial-misses-key-survival-goal\" target=\"_blank\" rel=\"noopener\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The US Food and Drug Administration (FDA) on Sunday declined to \u200capprove Summit Therapeutics\u2019 lung cancer drug ivonescimab, a setback for efforts to expand treatment for patients whose cancer has progressed after earlier therapies. In its so-called complete response letter, the FDA cited a late-stage trial showing that, while ivonescimab significantly delayed \u200bdisease progression, it did not demonstrate a statistically&#8230;<\/p>\n","protected":false},"author":1,"featured_media":101808,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_kad_blocks_custom_css":"","_kad_blocks_head_custom_js":"","_kad_blocks_body_custom_js":"","_kad_blocks_footer_custom_js":"","_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"categories":[16],"tags":[],"class_list":["post-101807","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pakistan"],"taxonomy_info":{"category":[{"value":16,"label":"Pakistan"}]},"featured_image_src_large":["https:\/\/newsvog.com\/ur\/wp-content\/uploads\/1794790532_FDA-1024x576.jpg",1024,576,true],"author_info":{"display_name":"frkhokhar@gmail.com","author_link":"https:\/\/newsvog.com\/ur\/author\/frkhokhargmail-com"},"comment_info":0,"category_info":[{"term_id":16,"name":"Pakistan","slug":"pakistan","term_group":0,"term_taxonomy_id":16,"taxonomy":"category","description":"All about Pakistan","parent":0,"count":10755,"filter":"raw","cat_ID":16,"category_count":10755,"category_description":"All about Pakistan","cat_name":"Pakistan","category_nicename":"pakistan","category_parent":0}],"tag_info":false,"_links":{"self":[{"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/posts\/101807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/comments?post=101807"}],"version-history":[{"count":1,"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/posts\/101807\/revisions"}],"predecessor-version":[{"id":101809,"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/posts\/101807\/revisions\/101809"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/media\/101808"}],"wp:attachment":[{"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/media?parent=101807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/categories?post=101807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newsvog.com\/ur\/wp-json\/wp\/v2\/tags?post=101807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}